<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596934</url>
  </required_header>
  <id_info>
    <org_study_id>R03DK074488</org_study_id>
    <secondary_id>R03DK074488</secondary_id>
    <secondary_id>Protocol 2145 (MCRU)</secondary_id>
    <secondary_id>Amylin Protocol 20050119</secondary_id>
    <secondary_id>DRDA 643938K3</secondary_id>
    <nct_id>NCT00596934</nct_id>
  </id_info>
  <brief_title>Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>Nonalcoholic Steatohepatitis: is Leptin an Etiological Factor (Phase 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elif Oral</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic steatohepatitis (or NASH) is known to be caused by deposition of fat in the
      liver and development of scarring. This condition occurs more frequently in overweight and
      obese persons. It is often associated with resistance to the actions of insulin hormone. Fat
      cells secrete a hormone called leptin. Recently, we have learned that obese or overweight
      persons make too much leptin, which may contribute to insulin resistance. Paradoxically,
      patients who do not have any fat cells, also have insulin resistance. In these patients,
      insulin resistance is caused by the absence of leptin and leptin replacement significantly
      improves insulin resistance and fat deposition in the liver. In an earlier study, we
      determined the leptin levels in patients with NASH and how these levels are related to body
      fat levels as well as responsiveness to insulin. We saw that a subgroup of patients with NASH
      have relatively low levels of leptin in contrast to the amount of body fat they had. We now
      would like to see if restoring leptin levels to normal will improve the disease process in
      these patients. Our study patients will be male patients, aged between 18 and 65 (inclusive),
      who do not have any other cause for their liver disease. We have put some restrictions in
      body size such that a spectrum of patients from normal weight to obese range would be
      included. They will also demonstrate low leptin levels (levels similar to only 25% of normal
      population). We will use a genetically engineered form of leptin manufactured by Amylin Inc.
      given via injections under the skin. We plan to continue therapy for a period of one year and
      evaluate the change in liver disease by a liver biopsy. We will also follow the metabolic
      parameters and body composition characteristics that we examined in our earlier study. We
      expect that patients with low blood leptin levels will show improvement in their liver
      disease and insulin resistance when their blood leptin levels are restored to normal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>Non-alcoholic steatohepatitis (NASH) score after approximately one year of treatment with metreleptin. Total NASH scores can range from 0 to 14. The higher the NASH score the more severe the liver disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>Body weight (kg) after one year of treatment on metreleptin for patients that completed 12 months of metreleptin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Fat Percentage by Magnetic Resonance Imaging (MRI - Dixon Method) at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>For determination of hepatic fat content by MRI and MR spectroscopy in patients, a series of out-phase and in-phase MRI at multiple flip angles are used. By combination of out-phase and in-phase MRI at multiple flip-angles and TE times, relaxation-time effects can be removed to yield quantitative intra-hepatic (and other organs') fractional fat content throughout the liver in a few breath-hold intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function Test: Alanine Aminotransferase (ALT) Values at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>ALT value in subjects that completed 12 months of metreleptin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function Test: Aspartate Aminotransferase (AST) Values at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>AST value in subjects that completed 12 months of metreleptin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose Value at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>Fasting glucose value in subjects that completed 12 months of metreleptin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Triglycerides Value at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>Fasting triglyceride value in subjects that completed 12 months of metreleptin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance: Homeostatic Model Assessment (HOMA) at 12 Months</measure>
    <time_frame>1 year</time_frame>
    <description>HOMA values in subjects that completed 12 months of metreleptin treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Fatty Liver Disease, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>Metreleptin treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metreleptin</intervention_name>
    <description>0.1 mg/kg/day once a day via subcutaneous injections</description>
    <arm_group_label>Metreleptin treatment group</arm_group_label>
    <other_name>(originally A100, recombinant-human-Methionyl-leptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven NASH

          -  Circulating fasting leptin &lt;9 ng/mL (staggered criteria for different BMI levels)

        Exclusion Criteria:

          -  Presence of advanced liver disease (as evidenced by abnormal synthetic function,
             abnormal prothrombin time or albumin)

          -  Presence of clinical lipodystrophy

          -  Presence of other liver disease

          -  Presence of clinical diabetes (fasting &gt;126 mg/dL or 2 hour post 75 g-glucose &gt;200
             mg/dL or random glucose &gt;200 mg/dL with presence of diabetes symptoms or known history
             of diabetes)

          -  Any medication for treatment of NASH or obesity

          -  Presence of HIV

          -  Inability to give informed consent

          -  Presence of end-stage renal disease, any type of active cancer, or &gt;class 2 congestive
             heart failure ((New York Heart Association Functional Classification System), based on
             medical history and physical examination

          -  Presence of any other condition that limits life expectancy to &lt;2 years

          -  Active infection (may be transient)

          -  Any other condition in the opinion of the investigators that may impede successful
             data collection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elif A Oral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uofmhealth.org/profile/83/elif-oral-md</url>
    <description>PIs Web site</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <results_first_submitted>August 22, 2016</results_first_submitted>
  <results_first_submitted_qc>October 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Elif Oral</investigator_full_name>
    <investigator_title>Associate Prof of Medicine</investigator_title>
  </responsible_party>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Obesity</keyword>
  <keyword>Leptin therapy</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment occurred from February 2007 and concluded in October 2007.</recruitment_details>
      <pre_assignment_details>One of ten enrolled participants screen failed during baseline visit, liver biopsy showed no non-alcoholic steatohepatitis. Therefore he is not included in any tables or analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NASH02</title>
          <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metreleptin Treatment Arm</title>
          <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" lower_limit="32" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-alcoholic steatohepatitis (NASH) score</title>
          <description>NASH scale: 0 - 14. The higher the NASH score the more severe the liver disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver fat percentage by Magnetic Resonance Imaging (MRI - Dixon method)</title>
          <description>For determination of hepatic fat content by MRI and MR spectroscopy in patients, a series of out-phase and in-phase MRI at multiple flip angles are used. By combination of out-phase and in-phase MRI at multiple flip-angles and TE times, relaxation-time effects can be removed to yield quantitative intra-hepatic (and other organs’) fractional fat content throughout the liver in a few breath-hold intervals.</description>
          <units>liver fat percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.0" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver function test: Alanine aminotransferase (ALT)</title>
          <description>Normal range for laboratory values: &lt;=35 IU/L</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver function test: Aspartate aminotransferase (AST)</title>
          <description>Normal range for laboratory values: 8 - 30 IU/L</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <description>Normal range for laboratory values: 73 - 100 mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.1" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Resistance: homeostatic model assessment (HOMA)</title>
          <description>HOMA values are based on fasting insulin and glucose concentrations and calculated as fasting insulin concentration (mU/L) x fasting glucose concentration (mg/dL)/405</description>
          <units>mU/L x mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting triglycerides</title>
          <description>Normal range for laboratory values: &lt;150 mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129.4" spread="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months</title>
        <description>Non-alcoholic steatohepatitis (NASH) score after approximately one year of treatment with metreleptin. Total NASH scores can range from 0 to 14. The higher the NASH score the more severe the liver disease.</description>
        <time_frame>1 year</time_frame>
        <population>Individuals who completed the year of metreleptin treatment and had follow-up liver biopsies after one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Arm</title>
            <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months</title>
          <description>Non-alcoholic steatohepatitis (NASH) score after approximately one year of treatment with metreleptin. Total NASH scores can range from 0 to 14. The higher the NASH score the more severe the liver disease.</description>
          <population>Individuals who completed the year of metreleptin treatment and had follow-up liver biopsies after one year.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Differences in each collected parameter will be evaluated using a paired t-test. If data are skewed such as in triglyceride levels, nonparametric tests will be used. P&lt;0.05 will be considered significant. If a significant difference can be demonstrated between baseline and 1-year results, a large scale, placebo-controlled trial will be designed using the data obtained from this pilot study</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight at 12 Months</title>
        <description>Body weight (kg) after one year of treatment on metreleptin for patients that completed 12 months of metreleptin treatment.</description>
        <time_frame>1 year</time_frame>
        <population>Subjects that completed 12 months of metreleptin treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Arm</title>
            <description>Treatment group
metreleptin: 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight at 12 Months</title>
          <description>Body weight (kg) after one year of treatment on metreleptin for patients that completed 12 months of metreleptin treatment.</description>
          <population>Subjects that completed 12 months of metreleptin treatment.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Fat Percentage by Magnetic Resonance Imaging (MRI - Dixon Method) at 12 Months</title>
        <description>For determination of hepatic fat content by MRI and MR spectroscopy in patients, a series of out-phase and in-phase MRI at multiple flip angles are used. By combination of out-phase and in-phase MRI at multiple flip-angles and TE times, relaxation-time effects can be removed to yield quantitative intra-hepatic (and other organs’) fractional fat content throughout the liver in a few breath-hold intervals.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Arm</title>
            <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Fat Percentage by Magnetic Resonance Imaging (MRI - Dixon Method) at 12 Months</title>
          <description>For determination of hepatic fat content by MRI and MR spectroscopy in patients, a series of out-phase and in-phase MRI at multiple flip angles are used. By combination of out-phase and in-phase MRI at multiple flip-angles and TE times, relaxation-time effects can be removed to yield quantitative intra-hepatic (and other organs’) fractional fat content throughout the liver in a few breath-hold intervals.</description>
          <units>liver fat percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <p_value_desc>p = 0.074</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Function Test: Alanine Aminotransferase (ALT) Values at 12 Months</title>
        <description>ALT value in subjects that completed 12 months of metreleptin treatment.</description>
        <time_frame>1 year</time_frame>
        <population>7 subjects who completed 12 months of metreleptin treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Arm</title>
            <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function Test: Alanine Aminotransferase (ALT) Values at 12 Months</title>
          <description>ALT value in subjects that completed 12 months of metreleptin treatment.</description>
          <population>7 subjects who completed 12 months of metreleptin treatment.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Function Test: Aspartate Aminotransferase (AST) Values at 12 Months</title>
        <description>AST value in subjects that completed 12 months of metreleptin treatment.</description>
        <time_frame>1 year</time_frame>
        <population>7 subjects who completed 12 months of metreleptin treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Group</title>
            <description>Treatment group
metreleptin: 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function Test: Aspartate Aminotransferase (AST) Values at 12 Months</title>
          <description>AST value in subjects that completed 12 months of metreleptin treatment.</description>
          <population>7 subjects who completed 12 months of metreleptin treatment.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose Value at 12 Months</title>
        <description>Fasting glucose value in subjects that completed 12 months of metreleptin treatment.</description>
        <time_frame>1 year</time_frame>
        <population>7 subjects who completed 12 months of metreleptin treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Arm</title>
            <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose Value at 12 Months</title>
          <description>Fasting glucose value in subjects that completed 12 months of metreleptin treatment.</description>
          <population>7 subjects who completed 12 months of metreleptin treatment.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Triglycerides Value at 12 Months</title>
        <description>Fasting triglyceride value in subjects that completed 12 months of metreleptin treatment.</description>
        <time_frame>1 year</time_frame>
        <population>7 subjects who completed 12 months of metreleptin treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Arm</title>
            <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Triglycerides Value at 12 Months</title>
          <description>Fasting triglyceride value in subjects that completed 12 months of metreleptin treatment.</description>
          <population>7 subjects who completed 12 months of metreleptin treatment.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.4" spread="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.195</p_value>
            <p_value_desc>p-value = 0.195.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance: Homeostatic Model Assessment (HOMA) at 12 Months</title>
        <description>HOMA values in subjects that completed 12 months of metreleptin treatment.</description>
        <time_frame>1 year</time_frame>
        <population>7 subjects who completed 12 months of metreleptin treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin Treatment Arm</title>
            <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance: Homeostatic Model Assessment (HOMA) at 12 Months</title>
          <description>HOMA values in subjects that completed 12 months of metreleptin treatment.</description>
          <population>7 subjects who completed 12 months of metreleptin treatment.</population>
          <units>mU/L x mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 months from patient baseline appointment.</time_frame>
      <desc>Adverse event data collected from patient's baseline study appointment till one month following patient's 12 month study appointment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metreleptin Treatment Arm</title>
          <description>Treatment group
metreleptin : 0.1 mg/kg/day once a day via subcutaneous injections</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>toxoplasmosis</sub_title>
                <description>add description of advent.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>right sternocleidomastoid lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>right axilla lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>left side muscle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>rectal pressure with ejaculation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>actinic keratoses</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a non-blinded, non-placebo controlled proof of concept trial. Out of the 9 patients, there were 7 completers.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Elif A. Oral</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-615-7271</phone>
      <email>eliforal@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

